Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Phase 3positiveSYCUME®Positive
AI Analysis
Summary
Innovent Biologics announced that its Phase 3 RESTORE-3 study of SYCUME® (Teprotumumab N01 Injection) met its primary endpoint, demonstrating significant improvement in proptosis with a 60.4% response rate in patients with inactive thyroid eye disease.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
RESTORE-3 study met primary endpoint with 60.4% response rate in proptosis and LS mean change from baseline of -1.88 mm in inactive thyroid eye disease
Importance:8/10
Sentiment:
0.85
Phase 3 positive dataophthalmologythyroid eye diseaseproptosisendpoint met
Related Companies
Read the original article
Published by PR Newswire Pharma on October 9, 2026 12:00 AM